Reports from Departments of Hospital Pharmacy Highlight Recent Findings in Inflammatory Bowel Disease (Comparative Effectiveness and Drug Survival of Biosimilar Infliximab Cpt-13 Vs. Reference Infliximab In Inflammatory Bowel Disease: a...).

A study conducted in Murcia, Spain compared the effectiveness, drug survival, and pharmacokinetic profiles of the biosimilar infliximab (CT-P13) and the reference infliximab (IFX) in patients with inflammatory bowel disease (IBD). The study found that both drugs had comparable efficacy, drug survival, pharmacokinetic profiles, and incidence of immunogenicity in a real clinical setting. However, further studies with greater statistical power are needed to validate these findings. This research has been peer-reviewed and published in Gastroenterologia y Hepatologia. [Extracted from the article]